Effects of Intraoperative Magnesium Sulfate on Perioperative Pain Relief After Spine Surgery
Primary Purpose
Analgesia, Pain, Postoperative, Spine Disease
Status
Completed
Phase
Phase 4
Locations
Greece
Study Type
Interventional
Intervention
Magnesium Sulfate
Isotonic saline 0.9%
Sponsored by
About this trial
This is an interventional treatment trial for Analgesia focused on measuring magnesium, analgesia, pain score, opioid consumption, spine surgery
Eligibility Criteria
Inclusion Criteria:
- Adult patients aged between 18 and 80 years
- ASA Physical status 1 to 3
- Elective or semi-elective lumbar laminectomy surgery
- Signed informed consent
Exclusion Criteria:
- Under medication with calcium channel blockers or magnesium
- Drugs or alcohol abuse
- Neurological disorders
- Myopathy
- Intracardiac block
- Hepatic failure
- Renal failure
- Pregnancy
Sites / Locations
- AHEPA University Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Magnesium sulfate
Isotonic solution 0.9%
Arm Description
Magnesium sulfate 20 mg/kg intravenous over a 15-min period before induction of anesthesia and 20 mg/kg/h by continuous i.v. infusion until surgery completion.
Isotonic solution 0.9% in the same volume as the study drug using identical pattern of administration.
Outcomes
Primary Outcome Measures
Analgesics consumption postoperatively in morphine equivalents
The difference in analgesic consumption (assessed as mg of morphine equivalents) postoperatively after intravenous infusion of magnesium sulfate or isotonic saline 0.9%
Secondary Outcome Measures
Analgesics consumption intraoperatively
The difference in analgesics consumption (μg of remifentanil) intraoperatively after /during intravenous infusion of magnesium sulfate or isotonic saline 0.9%
Pain intensity
The difference in pain intensity postoperatively assessed by Visual Analogue Scale, Numerical Pain Scale or Verbal Pain Scale after intravenous infusion of magnesium sulfate or isotonic saline 0.9%
Time to first analgesic request in minutes
The difference in the time frame (minutes) for analgesia request after emergence from anesthesia after intravenous infusion of magnesium sulfate or isotonic saline 0.9%
Full Information
NCT ID
NCT04161729
First Posted
November 3, 2019
Last Updated
May 13, 2020
Sponsor
Aristotle University Of Thessaloniki
1. Study Identification
Unique Protocol Identification Number
NCT04161729
Brief Title
Effects of Intraoperative Magnesium Sulfate on Perioperative Pain Relief After Spine Surgery
Official Title
Effects of Intraoperative Magnesium Sulfate on Pain Relief, Hemodynamics and Quality of Recovery After Spine Surgery
Study Type
Interventional
2. Study Status
Record Verification Date
May 2020
Overall Recruitment Status
Completed
Study Start Date
January 28, 2020 (Actual)
Primary Completion Date
May 3, 2020 (Actual)
Study Completion Date
May 5, 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Aristotle University Of Thessaloniki
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The treatment of postoperative pain is increasingly based on a multimodal approach and although opioids remain the drug of choice, they are often used in combination with other analgesics (paracetamol, cyclooxygenase inhibitors or non-steroidal anti-inflammatory drugs) and co-analgesic agents (clonidine and anti- NMDA such as ketamine or MgSO4). The rationale for combined analgesia is to achieve additive or synergistic analgesic properties while decreasing the incidence of side effects by reducing the dose of each agent. Nociceptive stimuli are known to activate the release of the excitatory amino acid glutamate in the dorsal horn of the spinal cord. The resultant activation of NMDA receptors causes calcium entry into the cell and triggers central sensitisation. This mechanism is involved in the perception of pain and mainly accounts for its persistence during the postoperative period.
Although magnesium is not a primary analgesic in itself, it enhances the analgesic actions of more established analgesics as an adjuvant agent. Magnesium produces a voltage-dependent block of NMDA receptors and has been reported to have analgesic properties that might be related to this inhibiting property. Magnesium sulfate has been reported to be effective in perioperative pain treatment and in blunting somatic, autonomic and endocrine reflexes provoked by noxious stimuli.
When magnesium was used intraoperatively, many researchers reported that it reduced the requirement for anesthetics and/or muscle relaxants.
Intraoperative use of magnesium sulfate can also be associated with decreased incidences of nausea and vomiting after surgery, which could have been due to the lower consumption of anesthetics (i.e. volatile agents), rather than any antiemetic effect of magnesium sulfate. In addition, perioperative i.v. administration of magnesium sulfate has another advantageous effect, as it decreases the incidence of shivering by up to 70-90%. Previous studies investigating the analgesic efficacy of MgSO4 in general, gynaecological, ophthalmic and orthopaedic surgery have shown conflicting results, while reports regarding spine surgery are extremely limited.
Our study was designed to investigate the effects of MgSO4 on perioperative pain relief and postoperative quality of recovery after lumbar laminectomy surgery.
Detailed Description
Each participant will receive standard monitoring (ECG, SpO2, capnography, SBP, oesophageal temperature, accelerography) and an intravenous access will be established. The level of anaesthesia will be monitored with the bispectral index (BIS), targeting to a BIS level 40-50.
Group M patients will receive intravenous magnesium sulfate 20 mg/kg over a 15-min period before induction of anaesthesia and 20 mg/kg/h by continuous i.v. infusion during the operation. Group C will be given isotonic solution of 0.9% in the same volume as the study drug.
A standard anesthesia protocol will be applied involving propofol 2mg/kg (iv) and fendanyl 2 μg/kg (iv). Cis-atracurium 0.2 mg/kg (iv) will be given to facilitate endotracheal intubation. Anaesthesia will be maintained with air 50% and oxygen 50%, and desflurane adjusted to achieve a target BIS between 40 and 50. Remifentanil will be added to the anesthesia regimen as needed.
Hemodynamic parameters will be recorded upon
Baseline: Before the administration of the tested drug
T5: 5 minutes after the administration of the tested drug
T10: 10 minutes after the administration of the tested drug
T15: 15 minutes after the administration of the tested drug
Ts: surgical incision
T30: 30 minutes after the administration of the tested drug
T45: 45 minutes after the administration of the tested drug
T60: 60 minutes after the administration of the tested drug
T90: 90 minutes after the administration of the tested drug
T120: 120 minutes after the administration of the tested drug
T180: 180 minutes after the administration of the tested drug
Low arterial blood pressure during surgery defined as a mean blood pressure value < 50 mmHg will be treated by a bolus of 5 mg ephedrine administered intravenously or phenylephirne civ for persistent hypotension.
Also, time to accelerography recording indicating the appropriateness of neuromuscular block for intubation, mean expired desflurane concentration (from 30 min after skin incision to the end of surgery), boluses of ephedrine and total intraoperative remifentanil consumption will be recorded.
Postoperative analgesic protocol will involve paracetamol 1 mg (iv), lornoxicam 8mg (iv) and morphine 3 mg (upon request).
Postoperatively pain assessment will be performed by Visual Analogue Scale (VAS), Verbal Rating Scale (VRS) and Numerical Rating Scale (NRS) at emergence from anesthesia and 2, 4, 6, and 24 h in the study period. Time to first analgesic request and total analgesics consumption postoperatively (morphine equivalents) will be recorded. Episodes of shivering, as well as episodes of nausea and vomiting (PONV), will be recorded at emergence and thereafter, throughout the study period. Finally, patients' global satisfaction will be assessed the first day after surgery using a 5-grade scale (1= worst discomfort ever experienced in their life and 5= totally satisfied during the immediate postoperative period).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Analgesia, Pain, Postoperative, Spine Disease
Keywords
magnesium, analgesia, pain score, opioid consumption, spine surgery
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
74 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Magnesium sulfate
Arm Type
Active Comparator
Arm Description
Magnesium sulfate 20 mg/kg intravenous over a 15-min period before induction of anesthesia and 20 mg/kg/h by continuous i.v. infusion until surgery completion.
Arm Title
Isotonic solution 0.9%
Arm Type
Placebo Comparator
Arm Description
Isotonic solution 0.9% in the same volume as the study drug using identical pattern of administration.
Intervention Type
Drug
Intervention Name(s)
Magnesium Sulfate
Intervention Description
Intravenous magnesium sulfate 20 mg/kg in 100ml isotonic saline 0.9% over a 15-min period before induction of anesthesia and 20 mg/kg/h by continuous i.v. infusion until surgery completion.
Intervention Type
Drug
Intervention Name(s)
Isotonic saline 0.9%
Intervention Description
Isotonic saline 0.9% 100ml over a 15-min period before induction of anesthesia and thereafter continuous i.v. infusion until surgery completion in dosage identical to magnesium sulfate group.
Primary Outcome Measure Information:
Title
Analgesics consumption postoperatively in morphine equivalents
Description
The difference in analgesic consumption (assessed as mg of morphine equivalents) postoperatively after intravenous infusion of magnesium sulfate or isotonic saline 0.9%
Time Frame
24 hours after the emergence from anesthesia
Secondary Outcome Measure Information:
Title
Analgesics consumption intraoperatively
Description
The difference in analgesics consumption (μg of remifentanil) intraoperatively after /during intravenous infusion of magnesium sulfate or isotonic saline 0.9%
Time Frame
180 minutes intraoperatively
Title
Pain intensity
Description
The difference in pain intensity postoperatively assessed by Visual Analogue Scale, Numerical Pain Scale or Verbal Pain Scale after intravenous infusion of magnesium sulfate or isotonic saline 0.9%
Time Frame
10 minutes after emergence from anesthesia, 2, 4 and 6 hours after the emergence from anesthesia
Title
Time to first analgesic request in minutes
Description
The difference in the time frame (minutes) for analgesia request after emergence from anesthesia after intravenous infusion of magnesium sulfate or isotonic saline 0.9%
Time Frame
24 hours after the emergence from anesthesia
Other Pre-specified Outcome Measures:
Title
Heart rate changes intraoperatively
Description
The changes in heart rate (beats per minute) intraoperatively after /during intravenous infusion of magnesium sulfate or isotonic saline 0.9%
Time Frame
180 minutes intraoperatively
Title
Systemic blood pressure changes intraoperatively
Description
The changes in systemic blood pressure (mmHg) intraoperatively after /during intravenous infusion of magnesium sulfate or isotonic saline 0.9%
Time Frame
180 minutes intraoperatively
Title
Postoperative adverse effects
Description
The incidence of shivering and nausea /vomiting after emergence from anesthesia after intravenous infusion of magnesium sulfate or isotonic saline 0.9%
Time Frame
24 hours after the emergence from anesthesia
Title
Patients' satisfaction
Description
The patients' global satisfaction assessed the day after surgery using a 5-grade scale (1= worst and 5= totally satisfied) after intravenous infusion of magnesium sulfate or isotonic saline 0.9%
Time Frame
24 hours after surgery
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Adult patients aged between 18 and 80 years
ASA Physical status 1 to 3
Elective or semi-elective lumbar laminectomy surgery
Signed informed consent
Exclusion Criteria:
Under medication with calcium channel blockers or magnesium
Drugs or alcohol abuse
Neurological disorders
Myopathy
Intracardiac block
Hepatic failure
Renal failure
Pregnancy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Georgia Tsaousi
Organizational Affiliation
Aristotle University Of Thessaloniki
Official's Role
Principal Investigator
Facility Information:
Facility Name
AHEPA University Hospital
City
Thessaloniki
ZIP/Postal Code
54636
Country
Greece
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Effects of Intraoperative Magnesium Sulfate on Perioperative Pain Relief After Spine Surgery
We'll reach out to this number within 24 hrs